MASTER AGREEMENTMaster Agreement • July 26th, 2021 • Quidel Corp /De/ • In vitro & in vivo diagnostic substances • Delaware
This MASTER AGREEMENT (this “Agreement”), dated as of July 24, 2021 (“Effective Date”), is entered into by and among Quidel Corporation, a Delaware corporation (“Quidel”), Quidel Cardiovascular Inc., a Delaware corporation and wholly-owned subsidiary of Quidel (“QCI”), and Beckman Coulter, Inc., a Delaware corporation (“Beckman”). Quidel, QCI and Beckman are each referred to as a “Party” and together as the “Parties”. Quidel and QCI shall be jointly and severally responsible and liable for the obligations or liabilities of either of them hereunder, and Quidel shall cause QCI to perform its obligations hereunder. Any action taken by either of Quidel or QCI hereunder (including, e.g., providing any notice hereunder) shall be binding on each of them and effective as if taken by both of them, and Quidel shall cause QCI not to act inconsistently with any actions or positions taken by Quidel with respect to this Agreement.
